Background. Hypertrophic cardiomyopathy (HCM) in pediatric solid organ transplant
recipients has been reported in association with use of calcineurin inhibitors. However, data …

Immunosuppression is the typical measure to prevent rejection after heart transplantation.
Although rejection is the usual cause of cardiac hypertrophy, numerous other factors warrant …

Purpose Our objective was to provide a contemporary analysis of a pediatric hypertrophic
cardiomyopathy (HCM) cohort and determine risk factors independently associated with …

We present 3 heart transplant recipients who developed hypertrophic cardiomyopathy years
after transplantation. In all 3 cases, the diagnosis was initially made based on …

Background Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder that
presents with a hypertrophied nondilated left ventricle. In the absence of other known …

Hypertrophic cardiomyopathy (HC) has historically been characterized as a disease of
substantial left ventricular hypertrophy, often associated with dynamic left ventricular outflow …

Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy,
manifesting as left ventricular hypertrophy in the absence of a secondary cause. The genetic …

Background: Surgical septal myectomy is the definitive treatment for relief of drug-refractory
symptoms in hypertrophic cardiomyopathy (HCM). Recent data document reduced survival …

Background—In hypertrophic cardiomyopathy (HCM), heart transplant has been
predominantly confined to patients with systolic dysfunction. An underappreciated HCM …

Introduction and objectives Posttransplant outcomes among recipients with a diagnosis of
hypertrophic cardiomyopathy (HCM) or restrictive cardiomyopathy (RCM) remain …